Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter January 1, 2007

Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability

Mojca Stegnar, Tjaša Vižintin Cuderman and Mojca Božič
From the journal


Background: Measurement of some haemostatic factors and products formed during activation of haemostasis seems to be promising in the determination of hypercoagulability.

Methods: The fibrinolytic variables euglobulin clot lysis time, tissue-type plasminogen activator, plasminogen activator inhibitor-1 and the haemostasis activation markers prothrombin fragment 1+2, thrombin-antithrombin complex and D-dimer were determined in 101 apparently healthy men and women aged 20–92 years (58±18 years, mean±SD) to establish variability due to several demographic, behavioural and metabolic factors.

Results: None of the fibrinolytic variables were affected by smoking, while tissue-type plasminogen activator antigen was significantly lower in women compared to men. Multiple regression analysis revealed several independent associations between tissue-type plasminogen activator, plasminogen activator inhibitor, body mass index and lipid levels, describing up to 40% of the variance in fibrinolytic variables. For haemostasis activation markers, no gender difference or effect of smoking was observed. Only D-dimer was independently associated with age. The haemostasis activation markers determined proved to be extremely sensitive to blood sampling procedure and were significantly higher in samples obtained by an untrained nurse compared to a trained nurse.

Conclusions: Fibrinolytic variables are predominantly modulated by age, body mass index and blood lipids, while haemostasis activation markers are mainly un-influenced by these factors.

Clin Chem Lab Med 2007;45:40–6.


Corresponding author: Prof. Dr. Mojca Stegnar, Department of Vascular Diseases, University Medical Centre, Zaloška 7, 1525 Ljubljana, Slovenia Phone: +386-1-5228052, Fax: +386-1-5228070,


1. Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med1993;117:71–7.Search in Google Scholar

2. Haeberli A. Prothrombin fragment F1+2. In: Jespersen J, Bertina RM, Haverkate F. Laboratory techniques in thrombosis – a manual. Dordrecht: Kluwer, 1999:217–22.Search in Google Scholar

3. Lau HK, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the thrombin antithrombin complex. J Biol Chem1980;255:5885–93.10.1016/S0021-9258(19)70713-3Search in Google Scholar

4. Hoffmeister HM, Heller W, Seipel L. Activation markers of coagulation and fibrinolysis: alterations and predictive value in acute coronary syndromes. Thromb Haemost1999;82(Suppl 1):76–9.10.1055/s-0037-1615559Search in Google Scholar

5. Meade TW, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolytic activity and clotting factors in ischaemic heart disease in women. Br Med J1996;312:1581.10.1136/bmj.312.7046.1581aSearch in Google Scholar

6. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet1993;342:1076–9.10.1016/0140-6736(93)92062-XSearch in Google Scholar

7. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet1993;341:1165–8.10.1016/0140-6736(93)90998-VSearch in Google Scholar

8. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet1987;2:3–9.10.1016/S0140-6736(87)93050-9Search in Google Scholar

9. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost1995;74:71–6.10.1055/s-0038-1642655Search in Google Scholar

10. Grimaudo V, Bachmann F, Hauert J, Christe MA, Kruithof EK. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism. Thromb Haemost1992;67:397–401.10.1055/s-0038-1648459Search in Google Scholar

11. Crowther MA, Roberts J, Roberts R, Johnston M, Stevens P, Skingley P, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost2001;85:390–4.10.1055/s-0037-1615594Search in Google Scholar

12. Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost1996;75:607–11.10.1055/s-0038-1650330Search in Google Scholar

13. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, et al. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation1992;85:1822–7.10.1161/01.CIR.85.5.1822Search in Google Scholar

14. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood2005;105:1102–5.10.1182/blood-2004-08-3253Search in Google Scholar

15. van der Bom JG, Bots ML, Haverkate F, Meijer P, Hofman A, Kluft C, et al. Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. Thromb Haemost2001;85:234–9.10.1055/s-0037-1615700Search in Google Scholar

16. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation1994;90:2236–40.10.1161/01.CIR.90.5.2236Search in Google Scholar

17. Fowkes FG, Lowe GD, Housley E, Rattray A, Rumley A, Elton RA, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet1993;342:84–6.10.1016/0140-6736(93)91288-WSearch in Google Scholar

18. Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol2001;21:1701–5.10.1161/hq1001.097020Search in Google Scholar PubMed

19. Lowe GD, Rumley A, Sweetnam PM, Yarnell JW, Rumley J. Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the caerphilly study. Thromb Haemost2001;86:822–7.10.1055/s-0037-1616138Search in Google Scholar

20. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation2001;103:2323–7.10.1161/01.CIR.103.19.2323Search in Google Scholar

21. Gaffney PJ, Creighton LJ, Perry MJ, Callus M, Thorpe R, Spitz M. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). I. Characterization and preliminary evaluation in plasma. Br J Haematol1988;68:83–90.10.1111/j.1365-2141.1988.tb04183.xSearch in Google Scholar PubMed

22. Reber G, de Moerloose P. D-dimer assays for the exclusion of venous thromboembolism. Semin Thromb Hemost2000;26:619–24.10.1055/s-2000-13217Search in Google Scholar PubMed

23. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost1995;73:374–9.10.1055/s-0038-1653783Search in Google Scholar

24. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol2001;21:611–7.10.1161/01.ATV.21.4.611Search in Google Scholar

25. Stegnar M, Peternel P, Keber D, Vene N. Poor fibrinolytic response to venous occlusion by different criteria in patients with deep vein thrombosis. Thromb Res1991;64:445–53.10.1016/0049-3848(91)90345-WSearch in Google Scholar

26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972;18:499–502.10.1093/clinchem/18.6.499Search in Google Scholar

27. MacCallum PK, Cooper JA, Howarth DJ, Meade TW, Miller GJ. Sex differences in the determinants of fibrinolytic activity. Thromb Haemost1998;79:587–90.10.1055/s-0037-1614950Search in Google Scholar

28. Stegnar M, Pentek M. Fibrinolytic response to venous occlusion in healthy subjects: relationship to age, gender, body weight, blood lipids and insulin. Thromb Res1993;69:81–92.10.1016/0049-3848(93)90005-9Search in Google Scholar

29. Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, et al. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost1986;55:330–2.10.1055/s-0038-1661557Search in Google Scholar

30. Ranby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem1986;32:2160–5.10.1093/clinchem/32.12.2160Search in Google Scholar

31. Mussoni L, Baldassarre D, Mannucci L, Sirtori CR, Tremoli E. Relationship between fibrinolytic and metabolic variables: a study in patients attending a lipid clinic. Ann Med2000;32:134–41.10.3109/07853890009011763Search in Google Scholar PubMed

32. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest2002;25:899–904.10.1007/BF03344054Search in Google Scholar PubMed

33. Wiman B. The role of the fibrinolytic system in thrombotic disease. Acta Med Scand Suppl1987;715:169–71.10.1111/j.0954-6820.1987.tb09918.xSearch in Google Scholar PubMed

34. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction – the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost1998;80:749–56.10.1055/s-0037-1615353Search in Google Scholar

35. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood1988;71:220–5.10.1182/blood.V71.1.220.220Search in Google Scholar

36. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol1988;70:327–33.10.1111/j.1365-2141.1988.tb02490.xSearch in Google Scholar PubMed

37. Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood1987;70:1645–53.10.1182/blood.V70.5.1645.1645Search in Google Scholar

38. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia1991;34:457–62.10.1007/BF00403280Search in Google Scholar PubMed

39. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost2003;1:1575–9.10.1046/j.1538-7836.2003.00279.xSearch in Google Scholar PubMed

40. Greenberg CS, Hursting MJ, Macik BG, Ortel TL, Kane WH, Moore BM. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. Clin Chem1994;40:1962–9.10.1093/clinchem/40.10.1962Search in Google Scholar

41. Becker RC, Bovill EG, Seghatchian MJ, Samama MM. Pathobiology of thrombin in acute coronary syndromes. Am Heart J1998;136:S19–31.10.1053/hj.1998.v136.93435Search in Google Scholar PubMed

42. Lippi G, Salvagno GL, Montagnana M, Brocco G, Guidi GC. Influence of short-term venous stasis on clinical chemistry testing. Clin Chem Lab Med2005;43:869–75.10.1515/CCLM.2005.146Search in Google Scholar PubMed

43. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle factors and coagulation activation markers: the Caerphilly Study. Blood Coagul Fibrinolysis2001;12:721–8.10.1097/00001721-200112000-00015Search in Google Scholar PubMed

44. Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem1993;39:683–6.10.1093/clinchem/39.4.683Search in Google Scholar

45. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol1997;97:775–84.10.1046/j.1365-2141.1997.1222936.xSearch in Google Scholar PubMed

46. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol1997;97:785–97.10.1046/j.1365-2141.1997.1232935.xSearch in Google Scholar PubMed

47. Lee AJ, Fowkes GR, Lowe GD, Rumley A. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol1995;15:1094–7.10.1161/01.ATV.15.8.1094Search in Google Scholar PubMed

Published Online: 2007-01-01
Published in Print: 2007-01-01

©2007 by Walter de Gruyter Berlin New York